Muramyl dipeptide
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- Muramyl dipeptide
- Molecular weight
- 492.48
- Structure (SMILES)
- CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(N)=O
- acetylmuramyl alanyl isoglutamine
- acetylmuramyl l alanyl d isoglutamine
- Acetylmuramyl-alanyl-isoglutamine
- ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE
- adagloxad simolenin with adjuvant
- matrix m1 adjuvant for bedside mixing
- MATRIX-M1 (Adjuvant) For Bedside Mixing
- Mdp (adjuvant)
- mdp adjuvant
- mFOLFOX (adjuvant)
- MOTS-c (MDP)
- muramyl dipeptide
- Muramyl dipeptide
- MURAMYL DIPEPTIDE [MI]
- muramyl dipeptide mi
- n acetylmuramoyl alanyl d isoglutamine
- n acetylmuramyl dipeptide
- n acetylmuramyl l alanine d isogln
- n acetylmuramyl l alanyl d isoglutamine
- N-(ACETYLMURAMOYL)ALANYL-D-ISOGLUTAMINE
- N-(ACETYLMURAMYL)-L-ALANYL-D-ISOGLUTAMINE
- N-acetylmuramyl dipeptide
- N-ACETYLMURAMYL-L-ALANINE-D-ISOGLN
- n2 n n acetylmuramoyl l alanyl d alpha glutamine
- N2-(N-(N-ACETYLMURAMOYL)-L-ALANYL)-D-ALPHA-GLUTAMINE
And 3 more, listed on the interactive page.
- CAS registry numbers
- 53678-77-6
- ChEMBL ID
- CHEMBL1779325
- InChIKey
- BSOQXXWZTUDTEL-QAQREVAFSA-N
- FDA ingredient codes (UNII)
- 2U7S2HVO96
- 11620162
- 91667728
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- muramyl dipeptide
- Type
- Natural product
- Drug name stem
- -tide
- Action
- Agonist
- Action type
- Agonist
- Target
- NLRP1
- Gene symbol
- NLRP1
- Protein identifier
- Q9C000
- Action
- Agonist
- Action type
- Agonist
- Target
- nucleotide binding oligomerization domain containing 2
- Gene symbol
- NOD2
- Protein identifier
- Q9HC29
Investigated indications
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
Trial references
- NCT00001042
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 8
- Polar surface area
- 246.84
- Calculated partition coefficient (ALogP)
- -4.33
- Calculated partition coefficient (XLogP)
- -3.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 12
- Heavy atoms
- 34
- Molecular formula
- C19H32N4O11
- Monoisotopic mass
- 492.20675785
- Natural product
- No
- Recorded assays
- 177
- Active assays
- 5
Active assay types
- Confirmatory
- Adjuvants, Immunologic
Related records
Trials (458)
- A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- A Clinical Study for Inactivated Vaccine Against EV71
- A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma
- A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy
- A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers
- A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
- A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
- A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
- A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
- A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
- A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants
- A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients
- A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
- A Phase II, Safety and Efficacy Study of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants
- A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
- A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets
In development for (1)
- HIV infectious disease Phase 1